Drug InfoNet.com
DrugInfoNet Home Page FAQ Drug Info Disease Info Manufacturer Info Health Care News Health Info Become Panelist Health Care Orgs Medical References Government Sites Hospital Sites Medical Schools
Search
Powered By HealthLine
Special Offers
Health Tools
 Arthritis Questions and Answers
 Arthritis Symptom Checker
 Arthritis Drug Information
 Preventing Arthritis
 Arthritis Treatment
Featured Conditions
 Osteoarthritis
 Chronic Pain
 Rheumatoid Arthritis
 Diet & Exercise
Resources
Healthscout News
3D Health Animations
Health Videos
Quizzes & Tools
Health Encyclopedia
Library & Communities
News Archive
Drug Library
Find a Therapist
Enter City or Zip Code:
Powered by Psychology Today



Channels
Home |  Today | Women| Men| Kids| Seniors| Diseases| Addictions| Sex & Relationships| Diet, Fitness, Looks| Alternative Medicine
 Printer Friendly  Send to a Friend

New Drug Helps Relieve Gout

Pegloticase normalized uric acid levels within 6 hours for participants in phase II trial


Related Encyclopedia
 border=
Alzheimer's Disease
Arthritis
Arthroscopy & Arthroscopic Surgery
Autoimmune Diseases and Disorders
More...

Related Healthscout Videos
 border=
Importance of Good Nutrition
Controlling Incontinence
Preventing Heart Disease the Easy Way
Lifestyle Changes for Heart Disease Prevention and Treatment
More...

Related Animations
 border=
Alzheimer's Disease Video Animation
Erectile Dysfunction
Rheumatoid Arthritis
What is a Heart Attack?
More...

Related Drug Information
 border=
Actonel
Coumadin
Detrol LA
Ditropan XL
More...

Related News Articles
 border=
Survive Stroke with Support
When the Caregiver Becomes the Patient
Vitamin D Deficit Could Lead to Heart Woes
Smokeout '08: The Perfect Time to Quit
More...

WEDNESDAY, Sept. 3 (HealthDay News) -- An experimental gout drug called pegloticase lowered levels of uric acid in the blood to target levels within a few hours in most patients.

That's the conclusion of a study by researchers at Duke University Medical Center and Savient Pharmaceuticals, the company that's developing the drug.

Text Continues Below



The phase II clinical trial included 41 patients randomly selected to receive either four or eight milligrams of pegloticase every two weeks, or eight or 12 milligrams every four weeks, for a 12- or 14-week period. The treatment is an infusion that takes about two hours.

Pegloticase normalized uric acid levels within six hours for participants in all dosage groups, and those levels were sustained throughout the treatment period in the two groups at the higher dosage levels. The most effective dose was found to be eight milligrams every two weeks, the study found.

During treatment, 88 percent of the patients experienced gout flares and some also experienced mild to moderate side effects, including reactions to the infusion and joint pain.

"The generally accepted goal of therapy is to reduce serum urate concentrations to less than 6 milligrams per deciliter, and we found that pegloticase can do that very, very quickly," study lead author Dr. John Sundy, a rheumatologist at Duke, said in a university news release.

"We were delighted to see this response, because all of the patients in our trial had already tried all the existing treatments for gout, and nothing was helping them," said Sundy, who added that more studies need to be conducted to confirm and expand the findings.

The findings were published online and were to be in the September issue of the journal Arthritis & Rheumatism. Results of a phase III study of pegloticase were expected to be presented in October at the annual meeting of the American College of Rheumatology, in San Francisco.

More information

The American Academy of Family Physicians has more about gout.



-- Robert Preidt

Copyright © 2008 ScoutNews, LLC. All rights reserved.
Last updated 9/3/2008

Related Links
 border=
From Healthscout's partner site on osteoarthritis, MyOsteoarthritisCentral.com
Understanding osteoarthritis symptoms and arthiritis pain
Learn about osteoarthritis treatments
How to avoid osteoarthritis with exercise





Duke University, news release, Sept. 2, 2008


We comply with the HONcode standard for trustworthy health
information:
verify here.
About The HealthScout Network Contact Us
Copyright © 2001-2008. The HealthCentralNetwork, Inc. All rights reserved.
Privacy Policy  Terms of Service    

FAQ Drug Info Disease Info Manufacturer Info Health Care News Health Info Become Panelist Health Care Orgs Medical References Government Sites Hospital Sites Medical Schools
Contact | Site Map | Search | Disclaimer | Mission Statement

© 1996-2003 DRUG INFONET, Inc. All rights reserved.